Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

Background CJM112 is a potent anti-IL-17A monoclonal antibody, whose clinical efficacy in psoriasis was recently documented. This study aimed to assess the effect of IL-17A blockade, using CJM112, in patients with moderate to severe acne. Methods A randomized, placebo-controlled, double-blind, paral...

Full description

Bibliographic Details
Main Authors: Diane M. Thiboutot, Noah Craft, Robert Rissmann, Ewa Gatlik, Malika Souquières, Julie Jones, Christian Loesche
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Journal of Dermatological Treatment
Subjects:
acne vulgaris
cjm112
anti-il-17a
inflammatory lesions
scarring
Online Access:http://dx.doi.org/10.1080/09546634.2022.2138691

Internet

http://dx.doi.org/10.1080/09546634.2022.2138691

Similar Items